Stock CGTX COGNITION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cognition Therapeutics, Inc.

Equities

CGTX

US19243B1026

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.95 USD +1.04% Intraday chart for Cognition Therapeutics, Inc. +5.98% +5.41%
04-12 Transcript : Cognition Therapeutics, Inc. - Special Call
03-26 Transcript : Cognition Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Evolution of the average Target Price on Cognition Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

30cae54ef87cb1fa2ff891a9d.uPomV7zNem2_AAwGlxytnVjV3fED1ctDpgU8MR8rtFQ.wMNRDfKHLFzUZllwpUPH-BO9hKBGmbx79nBIblV68i3dzxQ4xak0ANtGWQ~b317ced1d53a05daab90bcfa84ec122a

Analyst Recommendations on Cognition Therapeutics, Inc.

Ladenburg Thalmann Cuts Cognition Therapeutics' Price Target to $6 From $10, Keeps Buy Rating MT
B. Riley Cuts Cognition Therapeutics' PT to $5 From $15, Notes Near-Term Dilution, Expanding R&D Efforts to Execute on Phase II/III Programs; Keeps Buy Rating MT
Oppenheimer Adjusts Cognition Therapeutics Price Target to $9 From $18, Maintains Outperform Rating MT
Cantor Fitzgerald Starts Cognition Therapeutics at Overweight With $12 Price Target MT
Ladenburg Thalmann Starts Cognition Therapeutics at Buy With $10 Price Target MT
B. Riley Lowers Cognition Therapeutics' PT to $15 from $20, Keeps Buy Rating MT
Oppenheimer Adjusts Cognition Therapeutics' Price Target to $18 From $22, Maintains Outperform Rating MT
B. Riley Lowers Cognition Therapeutics' Price Target to $20 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
Oppenheimer Starts Cognition Therapeutics at Outperform with $22 PT On Potential Offered By Lead Dementia Drug Candidate CT1812 MT
B. Riley Starts Cognition Therapeutics at Buy with $27 PT, Notes Conviction in Proprietary, Mid-Stage Pipeline MT
Oppenheimer Starts Cognition Therapeutics at Outperform with $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.95 USD
Average target price
6.667 USD
Spread / Average Target
+241.88%
High Price Target
9 USD
Spread / Highest target
+361.54%
Low Price Target
5 USD
Spread / Lowest Target
+156.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cognition Therapeutics, Inc.

Ladenburg Thalmann
B. Riley
Oppenheimer
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CGTX Stock
  4. Consensus Cognition Therapeutics, Inc.